Citations

Showing 10 of 108162 citations.

A Case-Control Study of Accidental Falls During Surgical Hospitalizations
Morales, Diana J. Valencia , Laporta, Mariana L. , Schroeder, Darrell R. , Valencia Morales, Diana J , Schroeder, Darrell , Johnson, Rebecca L. , Šprung, Juraj , Weingarten, Toby N.

Mayo Clinic

The American Surgeon | April 18, 2021 | Volume: 89 | Issue: 1 | Pages: 61-68

10.1177/00031348211011114 | PMID 33870764 Get It

Background Postoperative falls are preventable complications. The study aims were to describe the rate and circumstances surrounding postoperative falls and explore potential associations with patient and procedural characteristics with emphasis on the use of sedative medications. Methods Medical records of hospitalized patients undergoing non-lower extremity surgery under general anesthesia from January 1, 2010, through April 30, 2018 were reviewed for falls within 72 postoperative hours. Perioperative use of sedatives, sleep aids, gabapentinoids, and opioids were abstracted. Each fall case was matched with two controls on age, sex, and procedure type. Descriptive statistics and multivariable analysis accounting for the matched design were performed. Results There were 343 falls among 200 186 hospitalized surgical patients (incidence of 17.1 [95% CI: 15.4, 19.0] falls per 10 000 procedures) with largest proportion of falls occurring on postoperative day 2 (n = 134, 39.1%). Most falls occurred in the general hospital wards (n = 304, 88.6%) and were unwitnessed (n = 186, 55.9%). The incidence of major injuries was 1.0 (95% CI: .1 – 3.6) per 100 000 procedures. Home use of non-benzodiazepine hypnotics (odds ratio 2.68, 95% CI: 1.47, 4.88, P=.001) and blood transfusions were associated with increased fall risk. Hospital stay was longer in patients who fall (7 [4, 15] vs. 5 [3, 9] days, P < .001). Conclusions The rate of postoperative falls in our institution was low and frequently unwitnessed. The use of non-benzodiazepine hypnotics is a modifiable risk factor associated with postoperative falls. Serious complications after falls were rare.
Complications Following Biologic Therapeutic Injections: A Multicenter Case Series
Eliasberg, Claire D. , Nemirov, Daniel , Mandelbaum, Bert R. , Pearle, Andrew D. , Tokish, John M. , Baria, Michael R. , Millett, Peter J. , Millett, Peter J , Shapiro, Shane A. , Rodeo, Scott A.

Mayo Clinic

Arthroscopy | April 17, 2021 | Volume: 37 | Issue: 8 | Pages: 2600-2605

10.1016/j.arthro.2021.03.065 | PMID 33872744 Get It

Purpose To describe the complications that occur following biologic therapeutic injections. Methods We queried physician members of the Biologic Association, a multidisciplinary organization dedicated to providing a unified voice for all matters related to musculoskeletal biologics and regenerative medicine. Patients included in this study must have (1) received a biologic injection, (2) sustained an adverse reaction, and (3) had a minimum of 1‐year follow‐up after the injection. Patient demographic information, medical comorbidities, diagnoses, and previous treatments were recorded. The type of injection, injection setting, injection manufacturers, and specific details about the complication and outcome were collected. Results In total, 14 patients were identified across 6 institutions in the United States (mean age 63 years, range: 36‐83 years). The most common injections in this series were intra‐articular knee injections (50%), followed intra‐articular shoulder injections (21.4%). The most common underlying diagnosis was osteoarthritis (78.5%). Types of injections included umbilical cord blood, platelet‐rich plasma, bone marrow aspirate concentrate, placental tissue, and unspecified “stem cell” injections. Complications included infection (50%), suspected sterile inflammatory response (42.9%), and a combination of both (7.1%). The most common pathogen identified from infection cases was Escherichia coli (n = 4). All patients who had isolated infections underwent treatment with at least one subsequent surgical intervention (mean: 3.6, range: 1‐12) and intravenous antibiotic therapy. Conclusions This study demonstrates that serious complications can occur following treatment with biologic injections, including infections requiring multiple surgical procedures and inflammatory reactions. Level of Evidence Level IV, case series.
Dynamic insulin‐stimulated mTOR/GSK3 signaling in peripheral immune cells: Preliminary evidence for an association with lithium response in bipolar disorder
Tye, Susannah J. , Borreggine, Kristin L., Price, J. Blair , Sutor, Shari L., Cuéllar‐Barboza, Alfredo B. , Biernacka, Joanna M. , Frye, Mark A. , Borreggine, Kristin, Biernacka, Joanna , Cuellar-Barboza, Alfredo , Tye, Susannah J , McElroy, Susan L.

Mayo Clinic

Bipolar Disorders | April 17, 2021 | Volume: 24 | Issue: 1 | Pages: 39-47

10.1111/bdi.13081 | PMID 33864716 Get It

AbstractIntroductionA key mechanism of lithium is the inhibition of glycogen synthase kinase‐3β (GSK3β) and activation of mammalian target of rapamycin (mTOR), two contributors to insulin signaling. We explored the relationship between these markers and clinical response to lithium in bipolar disorder (BD).MethodsThirty‐four subjects with BD who had been taking lithium for ≥2 years and had a maintenance lithium Alda score defined as either high (≥7; n = 20) or low (≤2; n = 14) were included in the study. Baseline protein expression of GSK3β and mTOR (total and phosphorylated (p)) was obtained from a buffy coat. Peripheral blood mononuclear cells (PBMCs) from a subset of each group (n = 11) were stimulated with insulin (10 µg) and change in protein expression was determined using Western blot.ResultsIn buffy coat samples, significantly higher levels of pmTOR were present in subjects with an Alda score ≤2 (lithium non‐responsive), relative to those with scores ≥7 (lithium‐responsive). No differences were observed for pGSK3β. In contrast, functional PBMC responses to 5 min of insulin stimulation demonstrated robust increases in pGSK3β (87.05 ± 43.41%) and pmTOR (105.7 ± 66.48%) in the lithium responsive group only. This contrasted observed decreases in pGSK3β (34.08 ± 16.12%) and pmTOR (37.84 ± 14.39%) 5 mins post‐insulin in non‐responders.ConclusionsDynamic increases in pmTOR and pGSK3β post‐insulin stimulation may reflect an immunometabolic state that facilitates lithium response. Further prospective analyses are needed to replicate and extend these preliminary findings and further investigate the role of insulin signaling in lithium response in BD.
Predictors of CMV Infection in CMV-Seropositive Kidney Transplant Recipients: Impact of Pretransplant CMV-Specific Humoral Immunity
Kirisri, Similan , Vongsakulyanon, Apirom , Kantachuvesiri, Surasak , Razonable, Raymund R. , Razonable, Raymund R , Bruminhent, Jackrapong

Mayo Clinic

Open Forum Infectious Diseases | April 17, 2021 | Volume: 8 | Issue: 6 | Pages: No page available

10.1093/ofid/ofab199 | PMID 34113686 Get It

Abstract Background Although cytomegalovirus (CMV)-seropositive solid organ transplant recipients have a relatively lower risk of CMV infection than CMV-seronegative recipients who receive allograft from CMV-seropositive donors, some patients remain at risk of CMV infection after transplant. We investigated the pretransplant CMV-specific humoral immunity (CHI) and other CMV infection predictors in CMV-seropositive kidney transplant (KT) recipients. Methods This retrospective study was conducted on adult CMV-seropositive KT recipients during 2017 and 2018. The cumulative incidence of CMV infection was estimated using the Kaplan-Meier method. CHI, measured with an enzyme-linked fluorescent immunoassay and other predictors for CMV infection, was analyzed using Cox proportional hazards models. Results Of the 340 CMV-seropositive KT recipients (37% female; mean ± SD age, 43 ± 11 years), 69% received deceased-donor allograft and 64% received induction therapy. During a mean follow-up of 14 months, the cumulative incidence of CMV infection was 14.8%. In multivariate analysis, low pretransplant CHI (defined as anti-CMV immunoglobulin [IgG] titer &lt;20 AU/mL) was significantly associated with CMV infection (hazard ratio [HR], 2.98; 95% CI, 1.31–6.77; P = .009). Other significant predictors of CMV infection included older donor age (HR, 1.03; 95% CI, 1.01–1.06; P = .005), antithymocyte induction therapy (HR, 2.90; 95% CI, 1.09–7.74; P = .033), and prolonged cold ischemic time (HR, 1.06; 95% CI, 1.02–1.10; P = .002). Conclusions A low pretransplant CHI is independently associated with post-transplant CMV infection in CMV-seropositive KT recipients. A quantitative anti-CMV IgG assay could potentially stratify CMV-seropositive patients at risk of CMV infection after KT.
The deep inferior epigastric lymphatic cable flap connected to gastroepiploic lymph node flap for treatment of refractory chylous ascites: Report of two cases
Ciudad, Pedro , Bustos, Samyd S. , Manrique, Oscar J. , Bolletta, Alberto , Forte, Antonio J. , Huayllani, María T. , Agko, Mouchammed , Urbina, J. Antonio, Date, Shivprasad , Kaya, Burak , Bolletta, Alberto , Forte, Antonio Jorge , Huayllani, Maria T , Mouchammed, Agko , Date, Shivprasad , Bustos, S S , Chen, Hung‐Chi

Mayo Clinic

Microsurgery | April 17, 2021 | Volume: 41 | Issue: 4 | Pages: 376-383

10.1002/micr.30736 | PMID 33864636 Get It

AbstractChylous ascites is the leakage of lipid‐rich lymph into the peritoneal cavity usually due to disruption of lymphatics or increased peritoneal lymphatic pressure. Various surgical options have been proposed to treat chylous ascites but most have shown suboptimal outcomes. The gastroepiploic vascularized lymph node (GE‐VLN) flap has been described previously for the treatment of lymphedema. In chylous ascites, this flap could provide an alternate drainage pathway for the intraperitoneal chylous fluid. The purpose of this report is to present another option for the microsurgical treatment of refractory chylous ascites. Herein, we report two patients with refractory chylous ascites secondary to cancer who have undergone deep inferior epigastric‐based lymphatic “cable” flap (DIE‐LCF) connected to a pedicle GE‐VLN flap. Patients were followed‐up for a minimum of 2 years. Within the first 3 months following surgery, the patient's nutritional parameters improved along with drastic reduction of ascites. At 2 years follow‐up postoperative abdominal circumference decreased significantly. None required further peritoneal paracentesis and all patients were free of chylous ascites symptoms. In conclusion, the DIE‐LCF connected to a pedicle GE‐VLN flap could be a feasible option for the microsurgical treatment of refractory chylous ascites.
Incidence, risk factors, treatment, and consequences of antibody‐mediated kidney transplant rejection: A systematic review
Hart, Allyson , Singh, Devender , Brown, Sarah , Wang, Jeffrey , Kasiske, Bertram L. , Singh, Devender

Mayo Clinic

Clinical Transplantation | April 17, 2021 | Volume: 35 | Issue: 7 | Pages: No page available

10.1111/ctr.14320 | PMID 33864724 Get It

Abstract Background Antibody‐mediated rejection (AMR) is a leading cause of kidney allograft failure, but its incidence, risk factors, and outcomes are not well understood. Methods We searched Ovid MEDLINE, Cochrane, EMBASE, and Scopus from January 2000 to January 2020 to identify published cohorts of ≥500 incident adult or 75 pediatric kidney transplant recipients followed for ≥1 year post‐transplant. Results At least two reviewers screened 5061 articles and abstracts; 28 met inclusion criteria. Incidence of acute AMR was 1.1%‐21.5%; most studies reported 3%‐12% incidence, usually within the first year post‐transplant. Few studies reported chronic AMR incidence, from 7.5%‐20.1% up to 10 years. Almost all patients with acute or chronic AMR received corticosteroids and intravenous immunoglobulin; most received plasmapheresis, and approximately half with rituximab. Most studies examining death‐censored graft failure identified AMR as an independent risk factor. Few reported refractory AMR rates or outcomes, and none examined costs. Most studies were single‐center and varied greatly in design. Conclusions Cohort studies of kidney transplant recipients demonstrate that AMR is common and associated with increased risk of death‐censored graft failure, but studies vary widely regarding populations, definitions, and reported incidence. Gaps remain in our understanding of refractory AMR, its costs, and resulting quality of life.
Artificial Intelligence in Plastic Surgery: Current Applications, Future Directions, and Ethical Implications
Jarvis, Tyler L. , Thornburg, Danielle A. , Rebecca, Alanna M. , Teven, Chad M. , Jarvis, Tyler, Thornburg, Danielle

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 17, 2021 | Volume: 8 | Issue: 10 | Pages: e3200

10.1097/gox.0000000000003200 | PMID 33173702 Get It

Background: Artificial intelligence (AI) in healthcare delivery has become an important area of research due to the rapid progression of technology, which has allowed the growth of many processes historically reliant upon human input. AI has become particularly important in plastic surgery in a variety of settings. This article highlights current applications of AI in plastic surgery and discusses future implications. We further detail ethical issues that may arise in the implementation of AI in plastic surgery. Methods: We conducted a systematic literature review of all electronically available publications in the PubMed, Scopus, and Web of Science databases as of February 5, 2020. All returned publications regarding the application of AI in plastic surgery were considered for inclusion. Results: Of the 89 novel articles returned, 14 satisfied inclusion and exclusion criteria. Articles procured from the references of those of the database search and those pertaining to historical and ethical implications were summarized when relevant. Conclusions: Numerous applications of AI exist in plastic surgery. Big data, machine learning, deep learning, natural language processing, and facial recognition are examples of AI-based technology that plastic surgeons may utilize to advance their surgical practice. Like any evolving technology, however, the use of AI in healthcare raises important ethical issues, including patient autonomy and informed consent, confidentiality, and appropriate data use. Such considerations are significant, as high ethical standards are key to appropriate and longstanding implementation of AI.
An Approach to Nonsuppressed Testosterone in Transgender Women Receiving Gender-Affirming Feminizing Hormonal Therapy
Maheshwari, Arvind , Nippoldt, Todd B., Davidge‐Pitts, Caroline , Nippoldt, Todd

Mayo Clinic

Journal of the Endocrine Society | April 17, 2021 | Volume: 5 | Issue: 9 | Pages: No page available

10.1210/jendso/bvab068 | PMID 34278180 Get It

AbstractNonsuppressed levels of testosterone are seen in up to a quarter of transgender women on gender-affirming feminizing hormonal treatment. Multiple factors contribute to this situation, including patient, medication, laboratory, and organ-specific concerns. We propose a stepwise approach to determine the etiology of nonsuppressed levels of testosterone in transgender women. This may lead to an appropriate feminizing hormonal therapy regimen and diagnosis of manageable medical conditions.
Guidelines for Using Finite Element to Model Cortical Defects
Gessel, G. R., Bartlett, J. P., An, Ki-yong, Morrey, B.F.

Mayo Clinic

ASME 1991 Computers in Engineering Conference: Volume 2 — Finite Elements/Computational Geometry; Computers in Education; Roboti | April 17, 2021 | Volume: No volume available | Issue: No issue available | Pages: 23-29

10.1115/cie1991-0092 Get It

Abstract Guidelines for using finite element to model cortical defects were established by determining the consequences for solution accuracy of various modeling strategies. Solution accuracy was established by comparing finite element results to an existing experimental benchmark for the torsion of circular tubes that contained transverse through circular holes. A new automated modeling approach was developed that could be used to support clinical modeling of cortical defects.
Assessment and Treatment of a Young Adult with Congenital Heart Disease and ADHD
Cassidy, Adam R. , Potts, Heather , Richardson, Alanna, Fogler, Jason , Fogler, Jason M , Hammerness, Paul Graves , Daly, Kevin P , Augustyn, Marilyn Christine

Mayo Clinic

Journal of Developmental & Behavioral Pediatrics | April 17, 2021 | Volume: 42 | Issue: 4 | Pages: 340-342

10.1097/dbp.0000000000000961 | PMID 33859122 Get It

CASE: Phillip is a young man born with hypoplastic left heart syndrome referred to your practice for a range of mental health concerns. He underwent palliation to an extracardiac Fontan in infancy and experienced multiple complications over the next decade including valvular regurgitation and arrhythmias necessitating a pacemaker. Phillip continued to have systolic heart failure with New York Heart Association class II symptoms, managed with 4 medications and anticoagulation. Despite this complex history, Phillip had intact cognitive abilities, achieved typical milestones, and performed well academically in secondary school. His first year of college proved to be more challenging, and Phillip presented to the outpatient psychiatry service with an acute depressive episode. His family history included depression, without known attention-deficit/hyperactivity disorder (ADHD). Treatment, including a selective serotonin reuptake inhibitor, cognitive behavioral therapy, and family support, led to near resolution of his symptoms of depression. In subsequent appointments, Phillip described a long history of inattention and disorganization with onset in childhood. This contributed to the decision to leave college, despite remission of symptoms of depression. Phillip was unable to study for any extended period without “perfect conditions,” described as the absence of potential distractions except for background music. Despite attempts to maintain “perfect conditions,” Phillip was often off task and “hyperfocusing” on irrelevant topics. Phillip struggled with planning and time management and would misplace items daily. Moreover, although the importance of self-care was well understood, Phillip often forgot to take his cardiac medication or to exercise, and he admitted to inconsistent sleep habits because of losing track of time. Based on a comprehensive psychiatric evaluation including retrospective report from a parent, Phillip was diagnosed with ADHD, coexisting with major depressive disorder, in remission. Significant ADHD symptoms were documented by interview, self-report, and administration of an abbreviated neuropsychological battery. Considering concerns regarding use of stimulants in a patient with congenital heart disease, including death, stroke, and myocardial infarction,1,2 how would you assess the risks-benefits of use of stimulants with Phillip? REFERENCES 1. Wilens TE, Prince JB, Spencer TJ, et al. Stimulants and sudden death: what is a physician to do? Pediatrics. 2006;118:1215–1219. 2. Zito JM, Burcu M. Stimulants and pediatric cardiovascular risk. J Child Adolesc Psychopharmacol. 2017;27:538–545.